Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) released its earnings results on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18, FiscalAI reports. The firm had revenue of $5.02 million for the quarter, compared to the consensus estimate of $4.51 million.

Here are the key takeaways from Verrica Pharmaceuticals’ conference call:

• Verrica said YCANTH demand accelerated in Q1, with U.S. revenue up 25.4% year over year and dispensed applicator units up 51.3%, including record monthly volume in March and further growth in April.
• The company highlighted commercial expansion efforts such as the YcanthRx pharmacy model, a growing sales force, and improved access tools that management believes are helping drive adoption and reimbursement.
• Verrica reported meaningful progress in its common warts Phase III program, with more than 50% of targeted enrollment reached in COVE-2 and plans to start COVE-3 by mid-2026.
• The company continues to advance VP-315 for basal cell carcinoma, pointing to strong Phase II data, regulatory alignment, and market research that suggests potential acceptance as a non-surgical or neoadjuvant option.
• Financially, Verrica ended the quarter with $20.6 million in cash and said that balance is expected to fund operations into the first quarter of 2027, while the quarterly net loss remained roughly flat year over year.

Verrica Pharmaceuticals Stock Down 5.3%

Shares of Verrica Pharmaceuticals stock traded down $0.39 during trading hours on Thursday, reaching $6.98. 23,334 shares of the company’s stock were exchanged, compared to its average volume of 126,695. The stock has a market cap of $119.93 million, a P/E ratio of -6.89 and a beta of 1.54. The company has a 50 day moving average of $6.02 and a two-hundred day moving average of $6.31. The company has a current ratio of 2.59, a quick ratio of 2.45 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $9.82.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC bought a new position in Verrica Pharmaceuticals in the fourth quarter valued at approximately $5,878,000. Velan Capital Investment Management LP bought a new stake in shares of Verrica Pharmaceuticals during the 4th quarter worth approximately $3,919,000. Boothbay Fund Management LLC acquired a new stake in shares of Verrica Pharmaceuticals in the 3rd quarter valued at approximately $1,210,000. Kalehua Capital Management LLC bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $1,959,000. Finally, Bank of America Corp DE increased its holdings in Verrica Pharmaceuticals by 347.5% during the fourth quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock worth $101,000 after buying an additional 111,678 shares during the last quarter. 42.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Zacks Research upgraded Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. Wall Street Zen downgraded Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.00.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.